Articles by Karine Tawagi, MD
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
The panel explains how the approval of subcutaneous nivo offers advantages in patient convenience and healthcare efficiency.
The panel weighs long-term treatment-free survival with nivo/ipi against the need for disease control with IO-TKI combos.
The panel considers the limitations of ctDNA from low tumor shedding but expresses optimism for detection technology.
The panel weighs the evolving role of biomarkers, particularly the promising blood-based biomarker KIM-1.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Four experts weigh in on their survey-based study of sequencing after 1L EV/pembro in the evolving landscape of la/mUC.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on COSMIC-313, CheckMate 9ER, KEYMAKER-U03, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CheckMate 274, NIAGRA, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on TALAPRO-2, studies on oligometastatic disease, and more.
The final segment of this roundtable series addresses the future of immunotherapy combinations.
The fifth segment of this roundtable series focuses on the use of circulating tumor DNA (ctDNA) in managing bladder cancer.
In part four of this roundtable, the use of immunotherapy in the adjuvant setting for bladder cancer is discussed.
The third segment of this roundtable series focuses on the latest developments in bladder cancer treatments.
In part two of this roundtable, multidisciplinary approaches to managing MIBC are discussed.
The first segment of this roundtable series focuses on the latest developments in MIBC treatment, including the NIAGARA trial
In the final part of this roundtable, Drs. Koshkin and Grivas discuss the use of EV/pembro and which patients are eligible.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.